Research Papers and Presentations

April 2017
Imprime PGG Modulates Immunosuppressive Myeloid Components of the Tumor Microenvironment and Drives Enhanced Anti-tumor Efficacy in Combination with Checkpoint Inhibitor Therapies
Poster presentation
American Association for Cancer Research (AACR) Annual Meeting
Washington, DC

Imprime PGG, a Novel Innate Immune Therapeutic in Phase 2 Clinical Development, Induces Mobilization of Monocytes and Focalized Recruitment of Innate Immune Cells to Tumor Sites
Poster presentation
American Association for Cancer Research (AACR) Annual Meeting
Washington, DC

A Novel Tumor Vaccine Platform: Direct Conjugation of Antigens to the β-glucan PAMP Imprime PGG Enhances Antigen Presentation and T Cell Priming
Poster presentation
American Association for Cancer Research (AACR) Annual Meeting
Washington, DC

March 2017
A Randomized, Open-label, Multicenter, Phase II Study Evaluating the Efficacy and Safety of BTH1677 (1,31,6 Beta Glucan; Imprime PGG) in Combination with Cetuximab and Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer
Peer-reviewed paper
Investigational New Drugs, 35(3), 345-358

February 2017
Imprime PGG Drives Innate Immune Activating Pharmacodynamic Changes in a Phase I Clinical Study in Healthy Human Volunteers
Poster presentation
American Society of Clinical Oncology (ASCO) – Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium
Orlando, FL, USA

November 2016
Imprime PGG, a Yeast β-Glucan PAMP Induces a Unique Cytokine Profile and Enhances Immune Checkpoint Inhibitor Therapy
Poster presentation
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Munich

Anti-beta Glucan Antibodies Represent a Mechanism-based Biomarker to Select Patients Responsive to the Novel Immunotherapeutic, Imprime PGG
Poster presentation
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 
Munich

Imprime PGG, a Novel Pathogen Associated Molecular Pattern (PAMP) Treatment Elicits M1-like Transcriptional Profile from Bone Marrow-derived Macrophages and Tumor Associated Macrophages (TAMs)
Poster presentation
Society for Immunotherapy of Cancer 
National Harbor, MD, USA

Imprime PGG, a Soluble Yeast β-glucan, is a Systemically Administered PAMP that Activates DCs and Supports T Cell Priming, Showing Synergy with Cancer Immunotherapies
Poster presentation
Society for Immunotherapy of Cancer
National Harbor, MD, USA

Immune Profiling via Multiplexed Immunofluorescence Shows that Imprime Based Anti-cancer Efficacy Involves Profound Changes in Macrophage Polarization, Type 1 IFN Signaling and the Formation of Immune Cell Clusters 
Poster presentation
Society for Immunotherapy of Cancer 
National Harbor, MD, USA

Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation
Peer-reviewed paper
PLOS ONE
DOI:10.1371/journal.pone.0165909

October 2016
Innate Immune Modulation: the Novel Immunotherapeutic Imprime PGG Triggers the Anti-cancer Immunity Cycle in Concert with Tumor-targeting, Anti-angiogenic and Checkpoint Inhibitor Antibodies
Poster presentation
AACR Tumor Immunology and Immunotherapy
Boston

September 2016
Imprime PGG, an Intravenously Administered β-glucan PAMP Activates the Innate Immune System: A Phase I Clinical Study to Evaluate Immunopharmacodynamic Responses
Poster presentation
CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival
New York

Imprime PGG, a Novel, Clinical-stage Pathogen Associated Molecular Pattern, Modulates MDSC Function, Facilitating a Coordinated Anti-tumor Immune Response
Poster presentation
CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival
New York

August 2016
BTH1677 in Combination with Cetuximab with and without Irinotecan in Patients with Advanced Metastatic Colorectal Cancer
Peer-reviewed paper
Colorectal Cancer
doi:10.2217/crc-2016-0010

July 2016
Characterization of the Therapeutically Active Immune Complex of Anti-Beta Glucan Antibodies and Imprime PGG, an Innate Immune Activating Carbohydrate PAMP
Poster presentation
International Carbohydrate Symposium
New Orleans

May 2016
Imprime PGG, a Yeast β-glucan PAMP Elicits a Coordinated Immune Response in Combination with Anti-PD-1 Antibody
Poster presentation
American Association of Immunologists
Seattle, Washington

April 2016
Imprime PGG Synergizes with Anti-angiogenic Antibodies to Repolarize the Immune Microenvironment, Suppressing Xenograft Tumor Growth In Vivo
Poster presentation
American Association for Cancer Research – 2016 Annual Meeting
New Orleans

Imprime PGG, a β-glucan PAMP (Pathogen-Associated Molecular Pattern) Activates the Direct Killing Functions of Innate Immune Cells in Concert with Tumor Targeting Antibodies
Poster presentation
American Association for Cancer Research – 2016 Annual Meeting
New Orleans

Imprime PGG Drives Adaptive Immune Resistance within the Tumor Microenvironment by Modulating the Myeloid Compartment and Enhances the Efficacy of Anti-PD1 Antibody In Vivo
Poster presentation
American Association for Cancer Research – 2016 Annual Meeting
New Orleans

Imprime PGG, a β-glucan PAMP (Pathogen-Associated Molecular Pattern), Effectively Elicits In Vivo Maturation of Antigen Presenting Cells in Mice and Humans, Suggesting Potential Synergy with Checkpoint Inhibitor Therapy
Poster presentation
American Association for Cancer Research – 2016 Annual Meeting
New Orleans

Imprime PGG Triggers PD-L1 Expression on Tumor and Myeloid Cells and Prevents Tumor Establishment in Combination with αPD-L1 Treatment In Vivo

Poster presentation
American Association for Cancer Research – 2016 Annual Meeting
New Orleans

February 2016
Two Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase 1 Studies Evaluating BTH1677, a 1, 3–1,6 Beta Glucan Pathogen Associated Molecular Pattern, in Healthy Volunteer Subjects
Investigational New Drugs: The Journal of New Anticancer Agent
DOI 10.1007/s10637-016-0325-z

January 2016
Imprime PGG, a Novel Pathogen Associated Molecular Pattern (PAMP) Re-orients the Suppressive Nature of M2-like Tumor Associated Macrophages (TAM) Ex Vivo and in In Vivo Tumor Model
Poster presentation
Keystone Symposia on Molecular and Cellular Biology – Cancer Immunotherapy: Immunity and Immunosuppression Meet Targeted Therapies 
Vancouver, British Columbia, Canada

November 2015
Imprime PGG Triggers a Coordinated Anti-cancer Immune Response in Concert with Antiangiogenic Antibodies, Re-polarizing the Immune Microenvironment to Suppress Tumor Growth
Poster presentation
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Boston, Massachusetts

Imprime PGG, a Soluble yeast β-glucan, Induces Dendritic Cell Maturation, Upregulating Co-stimulatory and Activation Markers to Enhance Antigen Presentation and T Cell Priming
Poster presentation
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Boston, Massachusetts

Imprime PGG, a Soluble Yeast β glucan, Primes Innate Immune Effector Cells to Recognize and Eradicate Tumor Cells
Poster presentation
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Boston, Massachusetts

Imprime PGG, an Innate Immunomodulator for Cancer Immunotherapy has the Potential to Modulate Macrophages in Tumor and Spleen to an Antitumor M1-like Phenotype
Poster presentation
Society for Immunotherapy of Cancer Annual Meeting
National Harbor, Maryland

October 2015
Imprime PGG Modulates the Myeloid Component of the Tumor Microenvironment to Coordinate an Anti-tumor Immune Response
Poster presentation
Fourth AACR International Conference on Frontiers in Basic Cancer Research
Philadelphia, Pennsylvania

Imprime PGG, a Yeast-derived Pathogen-Associated Molecular Pattern (PAMP) Drives a Coordinated Anti-cancer Immune Attack
Poster presentation
MD Anderson Cancer Center Symposia on Cancer Research 2015
Houston, Texas

September 2015
Imprime PGG Elicits Natural Killer Cell Activation, Potentiating Tumor Cell Killing
Poster presentation
AACR Inaugural International Cancer Immunotherapy Conference
New York, New York

Imprime PGG, a Soluble β-glucan, Binds to and Activates Dendritic Cells Resulting in Enhanced T Cell Priming, Expansion and Cytokine Production
Poster presentation
AACR Inaugural International Cancer Immunotherapy Conference
New York, New York

Imprime PGG Binds to Neutrophils Through Complement, Fc, and Dectin-1 Receptors, Priming These Cells for Enhanced ROS Production and Tumor Cell Cytotoxicity
Poster presentation
AACR Inaugural International Cancer Immunotherapy Conference
New York, New York

Imprime PGG Treatment Enhances Antibody-dependent Cellular Phagocytosis (ADCP) of Tumor Cells by Monocyte-derived Macrophages
Poster presentation
AACR Inaugural International Cancer Immunotherapy Conference
New York, New York

Endogenous Anti-β-glucan Antibodies and FcgRIIA (CD32a) Single Nucleotide Polymorphisms (SNP) as Potential Predictive Biomarkers for the Efficacy of Imprime PGG Immunotherapy in Cancer Patients
Poster presentation
AACR Inaugural International Cancer Immunotherapy Conference
New York, New York

Durability and Characteristics of Objective Tumor Responses with the Innate Immune Cell Modulator Imprime PGG in Combination with Standard of Care Frontline Treatment for Patients with Metastatic Non-Squamous NSCLC
Poster presentation
IASLC 16th World Conference on Lung Cancer
Denver, Colorado

August 2015
Chemical Modification of Yeast Cell Wall Beta Glucans to Enhance Stimulation of Innate Immune Cells Directed Toward Cancer Immunotherapy
Poster presentation
250th American Chemical Society National Meeting and Exposition
Boston, Massachusetts

Isolation and Characterization of an Immune Complex of Imprime PGG, a Cancer Immunotherapeutic Agent
Poster presentation
250th American Chemical Society National Meeting and Exposition
Boston, Massachusetts

June 2015
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG in Combination with Cetuximab in Patients with KRAS Wild Type Colorectal Cancer
Poster presentation
2015 ASCO Annual Meeting
Chicago, Illinois

May 2015
A Phase (Ph) 1/2 Trial of Rituximab (RX), Imprime PGG (IP), and Alemtuzumab (AL) in the Early Treatment of Patients (Pts) with High Risk Chronic Lymphocytic Leukemia (CLL)
Poster presentation
2015 ASCO Annual Meeting
Chicago, Illinois

Durability and Characteristics of Objective Tumor Responses with the Innate Immune Cell Modulator Imprime PGG in Combination with Standard of Care Frontline Treatment for Patients (Pts) with Metastatic Non-Squamous NSCLC
Poster presentation 
2015 ASCO Annual Meeting
Chicago, Illinois

Safety of Imprime PGG, A Novel Innate Immune Cell Modulator, in Adults With Stage IV Non-small Cell Lung Cancer: An Integrated Analysis of Two Randomized Phase 2 Studies
Poster presentation 
2015 ASCO Annual Meeting
Chicago, Illinois

Modification of the Degree of Branching of a Beta-(1,3)-Glucan Affects Aggregation Behavior and Activity in an Oxidative Burst Assay
Biopolymers 103: 665–674, 2015

Imprime PGG, a Yeast β-glucan Immunomodulator has the Potential to Modulate the Subtypes of Immunosuppressive M2 Macrophages
Poster presentation
American Association of Immunologists Annual Meeting 
New Orleans, Louisiana 

April 2015
Imprime PGG Decreases Regulatory T Cell Suppression and Enhances T cell Proliferation and Differentiation Revealing Additional Mechanisms for its Anti-tumor Activity
Poster presentation
American Association for Cancer Research Annual Meeting 2015 
Philadelphia, Pennsylvania 

Imprime PGG Modulates the Function of Monocyte-derived M2 Macrophages and Dendritic Cells to Drive T-cell Expansion
Poster presentation
American Association for Cancer Research Annual Meeting 2015 
Philadelphia, Pennsylvania 

Imprime PGG Treatment Elicits a Coordinated Anti-tumor Immune Response That Triggers Enhanced Expression of PD-L1 on Tumor Cells as well as Monocyte-derived Macrophages and Dendritic Cells
Poster presentation
American Association for Cancer Research Annual Meeting 2015
Philadelphia, Pennsylvania

Imprime PGG Conjugated Directly to Protein Enables Cross-presentation of Antigen that Generates Multifunctional Cytotoxic T Cells
Poster presentation
American Association for Cancer Research Annual Meeting 2015
Philadelphia, Pennsylvania 

Efficacy and Safety of Imprime PGG, a Novel Innate Immune Modulator, in Combination with Bevacizumab (Bev), Carboplatin and Paclitaxel for the 1st-Line Treatment of Stage IV NSCLC
Poster presentation
European Lung Cancer Conference (ELCC)
Geneva, Switzerland

March 2015
Imprime PGG, a Yeast β-glucan Immunomodulator, Enhances Maturation and Function of Human Monocyte-Derived Dendritic Cells
Poster presentation
2015 Keystone Symposium: Dendritic Cells and Macrophages Reunited
Montreal, Canada

February 2015
Imprime PGG, a Yeast β-glucan Immunomodulator, Can Engage Fc Gamma Receptor (FcγR) in Addition to Complement Receptor 3 (CR3) on Human Neutrophils and Monocytes
Poster presentation
2015 Keystone Symposia Conference
Banff, Alberta, Canada  

January 2015
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG in Combination with Cetuximab in Patients with KRAS Wild Type Colorectal Cancer
Poster presentation
Gastrointestinal Cancers Symposium
San Francisco, CA

November 2014
Safety of Imprime PGG, a Novel Innate Immune Modulator, in Adults With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Poster presentation
ESMO Symposium on Immuno-Oncology 2014
Geneva, Switzerland

A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG in Combination with Cetuximab in Patients with KRAS Wild Type Colorectal Cancer 
Poster presentation
Society for Immunotherapy of Cancer
National Harbor, MD

September 2014
Chemoimmunotherapy of Advanced Non-Small Cell Lung Cancer with Imprime PGG in Combination with Cetuximab, Carboplatin and Paclitaxel – Analysis of Secondary Endpoints of a Multicenter, Randomized Phase 2 Trial
Poster presentation
European Society of Medical Oncology Congress 2014
Madrid, Spain

Imprime PGG, A Novel Innate Immune Modulator, in the 1st-line Treatment of Stage IV NSCLC: Results From a Randomized, Controlled, Multicenter Phase 2 Study
Poster presentation
European Society of Medical Oncology Congress 2014
Madrid, Spain

Endogenous Anti-ß-Glucan Antibodies, a Potential Predictive Biomarker for the Efficacy of Soluble Yeast ß-1,3/1,6 Glucan (Imprime PGG) Immunotherpay in cancer patients
Poster presentation
The American Association of Immunologists Annual Meeting
Pittsburgh, PA

April 2014
Identification of a Critical Level of Anti-Beta Glucan IgG Antibody Necessary for Response to Soluble Beta-Glucan Therapy and its Application as a Biomarker for Analysis in Clinical Trials
Poster presentation
American Association for Cancer Research Annual Meeting
San Diego, CA

March 2014
Pharmacokinetic Analysis of β-Glucan Following Administration of Imprime PGG, a Novel β-Glucan Immunomodulator Being Developed for the Treatment of Non-Small Cell Lung Cancer 
Poster presentation
American Society for Clinical Pharmacology and Therapeutics 
Atlanta, GA

PGG β-Glucan With Carboplatin, Paclitaxel and Cetuximab for Chemoimmunotherapy of Advanced Non-Small Cell Lung Cancer (NSCLC)
Poster presentation
ESMO European Lung Cancer Conference
Geneva, Switzerland

From Pariah to Darling: Biopharma Finally Courts Immunotherapies
Panel discussion with Myra Patchen, Ph.D.
Bio Europe, Turin, Italy

January 2014
Differential Regulation of Oxidative Burst by Distinct β-Glucan-Binding Receptors and Signaling Pathways in Human Peripheral Blood Mononuclear Cells
Glycobiology (2014) 24 (4): 379-391

The Use of Carbohydrate Antibody Conjugates to Stimulate and Direct Innate Immune Cells to Recognize and Kill Cancer Cells
Poster Presentation
Cambridge Healthtech Institute’s Antibody-Drug Conjugates/ Engineering Targeted Therapeutics Conference
Palm Springs, CA

Imprime PGG improves the efficacy of carboplatin, paclitaxel and cetuximab chemoimmunotherapy of advanced non-small cell lung cancer (NSCLC)
Poster presentation
American Association for Cancer Research and the International Association for the Study of Lung Cancer Joint Conference on the Molecular Origins of Lung Cancer
San Diego, CA

December 2013
The Challenges of Developing Immune Biomarkers for Cancer Immunotherapy
Oral presentation by Mary Antonysamy, Ph.D., Vice President of Preclinical and Translational Research
VIC Congress – Vaccines, Immunotherapies and Cell Therapies
Brussels, Belgium

September 2013
Immune Cell Priming and Potentiation of Anti-Tumor Effects by Imprime PGG
Poster presentation
Frontiers in Basic Cancer Research
National Harbor, Maryland

August 2013
Binding of soluble yeast β-glucan to human neutrophils and monocytes is complement-dependent
Frontiers in Immunology. 2013; 4: 230
Published online 12 August 2013 | doi: 10.3389/fimmu.2013.00230

A Novel Mechanism for Recognition of a Small Molecule Carbohydrate Immunotherapeutic by Human Myeloid Cells: Potential for Modulation of Efficacy in the Clinic
Poster presentation
International Congress of Immunology
Milan, Italy

May 2013
Recognition of soluble yeast β-1,3/1,6 glucan by complement receptor 1 is essential for it to bind complement receptor 3 on human neutrophils and monocytes, and complement receptor 2 on B cells
Poster presentation
American Association of Immunologists Annual Meeting
Honolulu, Hawaii

January 2013
Immunomodulatory effects of soluble yeast β-1,3/1,6 glucan on human immune B cells
Poster presentation
Gordon Research Conference Immunology of Fungal Infections
Galveston, Texas

Activation of the Classical Complement Pathway is Required for Cancer Immunotherapy Efficacy Involving the Combination of Anti-Tumor Monoclonal Antibody and Soluble Yeast β-1,3/1,6 Glucan (Imprime PGG) 
Poster presentation
Cancer Immunology and Immunotherapy Conference (Keystone Symposia)
Vancouver, British Columbia, Canada